Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;60(7):1771-1779.
doi: 10.1007/s00127-024-02769-0. Epub 2024 Sep 20.

Frequency of self-reported persistent post-treatment genital hypoesthesia among past antidepressant users: a cross-sectional survey of sexual and gender minority youth in Canada and the US

Yassie Pirani  1   2 , J Andrés Delgado-Ron  3 , Pedro Marinho  4 , Amit Gupta  5   6 , Emily Grey  1 , Sarah Watt  3 , Kinnon R MacKinnon  7 , Travis Salway  8   9
Affiliations

Frequency of self-reported persistent post-treatment genital hypoesthesia among past antidepressant users: a cross-sectional survey of sexual and gender minority youth in Canada and the US

Yassie Pirani et al. Soc Psychiatry Psychiatr Epidemiol. 2025 Jul.

Abstract

Purpose: Persistent post-treatment genital hypoesthesia (PPTGH) is a primary symptom of post-SSRI sexual dysfunction (PSSD), an iatrogenic syndrome characterized by enduring sexual dysfunction following the discontinuation of some antidepressants. We aimed to estimate the frequency of PPTGH among past users of psychiatric treatments, particularly antidepressants.

Methods: We used a subsample of UnACoRN, a US/Canada survey of sexual and gender minority youth aged 15 to 29. We included participants with a history of psychiatric drug use. We excluded individuals with genital surgeries or without sexual experience. The analysis involved chi-square tests for initial group comparisons, post hoc tests for multiple comparisons, and logistic regression among those who had stopped taking medication. We exponentiated the regression to estimate the odds of PPTGH by drug type, adjusting for age, sex-assigned-at-birth, hormone treatment, and depression severity in three nested models.

Results: 574 of 2179 survey participants reported genital hypoesthesia. They were older and more likely to report male sex assignment at birth, hormonal therapy history, and psychiatric drug history. The frequency of PPTGH among antidepressant users was 13.2% (93/707) compared to 0.9% (1/102) among users of other medications; adjusted odds ratio: 14.2 (95% CI: 2.92 to 257).

Conclusion: Antidepressant discontinuation is strongly associated with PPTGH in the US and Canada where SSRI/SNRI medications account for 80% of antidepressant prescriptions. We call for standardized international warnings and transparent, informed consent. Future research should expand upon our efforts to estimate the risk of PSSD by including all the proposed diagnostic criteria, including documentation of temporal changes in PSSD-related symptoms before and after treatment (≥3 months).

Keywords: Long term adverse effects; PSSD; Selective serotonin reuptake inhibitors; Serotonin and norepinepherine reuptake inhibitors; Sexual dysfunction.

Plain language summary

This study explored the long-lasting sexual side effects—specifically, reduced genital sensitivity—of certain antidepressants, even after stopping the medication, in a diverse group of young people, primarily those identifying as sexual and gender minorities. We analyzed responses from a large survey, focusing on participants with a history of psychiatric drug use but without genital surgeries. Our findings indicate that those who used antidepressants experienced a substantial increase in reports of reduced genital sensitivity—13.2% of antidepressant users compared to 0.9% of users of other medications. This symptom is more common among individuals who had used antidepressants and sedatives. Our results emphasize the necessity for clear warnings and proper consent processes about potential long-term sexual side effects, particularly for young patients, and standardization of these procedures across countries. Further research is needed to explore this condition more deeply, including studies of all related symptoms and their development over time before and after treatment.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval: Ethical approval was provided by the Simon Fraser University Research Ethics Board (#30000544). Competing interests: The authors declare no competing interests.

Similar articles

See all similar articles

References

    1. Healy D, Le Noury J, Mangin D (2018) Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases. Int J Risk Saf Med 29:125–134. https://doi.org/10.3233/JRS-180744 - DOI - PubMed - PMC
    1. Reisman Y (2020) Post-SSRI sexual dysfunction. BMJ 368:m754. https://doi.org/10.1136/bmj.m754 - DOI - PubMed
    1. Chinchilla Alfaro K, van Hunsel F, Ekhart C (2022) Persistent sexual dysfunction after SSRI withdrawal: a scoping review and presentation of 86 cases from the Netherlands. Expert Opin Drug Saf 21:553–561. https://doi.org/10.1080/14740338.2022.2007883 - DOI - PubMed
    1. Reisman Y (2017) Sexual consequences of Post-SSRI syndrome. Sex Med Rev 5:429–433. https://doi.org/10.1016/j.sxmr.2017.05.002 - DOI - PubMed
    1. Waraich A, Yih J, Goldstein S, Goldstein I (2021) 076 Post-SSRI sexual dysfunction (PSSD): ten Year Retrospective Chart Review. J Sex Med 18:S41. https://doi.org/10.1016/j.jsxm.2021.01.046 - DOI

MeSH terms

Substances

LinkOut - more resources